This Article Full Text Full Text (PDF) All Versions of this Article: 1055-9965.EPI-08-0380v1 17/9/2337    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rohan, T. E. Articles by Page, D. L. Search for Related Content PubMed PubMed Citation Articles by Rohan, T. E. Articles by Page, D. L.

Estrogen plus Progestin and Risk of Benign Proliferative Breast Disease

¹ Albert Einstein College of Medicine, Bronx, New York; ² Harbor-UCLA Medical Center, Torrance, California; ³ New Jersey Medical School, Newark, New Jersey; ⁴ Fred Hutchinson Cancer Research Center, Seattle, Washington; ⁵ University of Texas Health Science Center, San Antonio, Texas; and ⁶ Vanderbilt University Medical School, Nashville, Tennessee

Requests for reprints: Tom Rohan, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. Phone: 718-430-3355; Fax: 718-430-8653. E-mail: rohan{at}aecom.yu.edu

Women with benign proliferative breast disease are at increased risk of subsequent breast cancer. Estrogens and progesterone exert proliferative effects on mammary epithelium, and combined hormone replacement therapy has been associated with increased breast cancer risk. We tested the effect of conjugated equine estrogen plus progestin on the risk of benign proliferative breast disease in the Women's Health Initiative (WHI) randomized controlled trial. In the WHI trial of estrogen plus progestin, 16,608 postmenopausal women were randomly assigned either to 0.625 mg/day of conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate or to placebo. Baseline and annual breast exams and mammograms were required. The trial was terminated early (average follow-up, 5.5 years). We identified women who had had a biopsy for benign breast disease, and subjected histologic sections from the biopsies to standardized review. Overall, 178 incident cases of benign proliferative breast disease were ascertained in the estrogen plus progestin group and 99 in the placebo group. The use of estrogen plus progestin was associated with a 74% increase in the risk of benign proliferative breast disease [hazard ratio, 1.74; 95% confidence interval (CI), 1.35-2.25]. For benign proliferative breast disease without atypia the hazard ratio was 2.00 (95% CI, 1.50-2.66), while for atypical hyperplasia it was 0.76 (95% CI, 0.38-1.52). The risk varied little by levels of baseline characteristics. The results of this study suggest that the use of estrogen plus progestin may increase the risk of benign proliferative breast disease. (Cancer Epidemiol Biomarkers Prev 2008;17(9):2337–43)

This article has been cited by other articles:

				T. A. Rose-Hellekant, A. J. Skildum, O. Zhdankin, A. L. Greene, R. R. Regal, K. D. Kundel, and D. W. Kundel Short-term Prophylactic Tamoxifen Reduces the Incidence of Antiestrogen-Resistant/Estrogen Receptor-Positive/Progesterone Receptor-Negative Mammary Tumors Cancer Prevention Research, May 1, 2009; 2(5): 496 - 502. [Abstract] [Full Text] [PDF]